Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

ConjuChem Biotechnologies establishes special committee to explore strategic alternatives

ConjuChem Biotechnologies, Inc. (TSX: CJB) announced today that it has established a Special Committee of independent Board members to explore and evaluate all strategic alternatives including, but not limited to, a sale of the Company or the sale of all or a substantial part of its assets.

20 Jan 2010

Access Pharmaceuticals provides update on its Cobalamin insulin development program

ACCESS PHARMACEUTICALS, INC. provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.

20 Jan 2010

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting early-stage discovery research programs for the life science industry -- to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).

20 Jan 2010

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance the use of insulin pumps.

From BD (Becton, Dickinson and Company) 20 Jan 2010

Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed

Oramed Pharmaceuticals Inc. announced today the completion of patient enrollment in the Phase 2B clinical study of its oral insulin capsule, ORMD-0801.

20 Jan 2010

CBAI collaborates with Center for Stem Cell Awareness to re-sell its stem cell collection and storage services

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has contracted with The Center for Stem Cell Awareness to re-sell its stem cell collection and storage services.

19 Jan 2010

Medpro Safety Products purchases product development rights from Visual Connections

MedPro Safety Products, Inc., a leading developer of transformational technologies that enable safer medication delivery and blood collection systems, has purchased product development rights for a unique, fully passive Insulin Guard self-injector from Visual Connections, owned by Hooman Asbaghi. Mr. Asbaghi is the inventor of MedPro’s fully passive phlebotomy collection devices, which include two versions of a safety blood collection holder, a passive IV catheter, and a safety blood collection set.

19 Jan 2010

Down syndrome and Alzheimer's disease are the same

Nearly 20 years ago Huntington Potter kicked up a storm of controversy with the idea that Down syndrome and Alzheimer's were the same disease. Now the evidence is in: He was right.

18 Jan 2010

MAGIC investigators identify new genetic variants that influence insulin and glucose regulation

An international research consortium has found 13 new genetic variants that influence blood glucose regulation, insulin resistance, and the function of insulin-secreting beta cells in populations of European descent. Five of the newly discovered variants increase the risk of developing type 2 diabetes, the most common form of diabetes.

18 Jan 2010

Researchers identify new gene variants associated With glucose, insulin levels

A major international study with leadership from Massachusetts General Hospital (MGH) researchers has identified 10 new gene variants associated with blood sugar or insulin levels. Two of these novel variants and three that earlier studies associated with glucose levels were also found to increase the risk of type 2 diabetes. Along with a related study from members of the same research consortium, associating additional genetic variants with the metabolic response to a sugary meal, the report will appear in Nature Genetics and has been released online.

18 Jan 2010

Fourth edition of IDF Diabetes Atlas reports high incidence of diabetes in developing countries

...

18 Jan 2010

Evidence suggests insulin pumps may help in maintaining blood glucose levels in type 1 diabetic patients

A new evidence review suggests that using a pump to deliver insulin continuously — instead of taking three or more daily injections — might result in better control of blood sugar for people with type 1 diabetes.

18 Jan 2010

Researchers uncover novel genetic markers for diabetes-related traits

In two major studies published in Nature Genetics today, researchers use biological understanding to dissect the genetics of diabetes. An international team comprising researchers from more than 100 institutions analysed vast suites of genetic data from more than 100,000 people of European descent to uncover the associations.

18 Jan 2010

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

The Juvenile Diabetes Research Foundation today announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease -- the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels.

18 Jan 2010

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.

13 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

Green tea could modulate smoke-induced lung cancer

Drinking green tea could modulate the effect of smoking on lung cancer. Results of this hospital-based, randomized study conducted in Taiwan were presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held here from Jan. 11-14, 2010.

13 Jan 2010

ProtoKinetix’ AAGP raises hope for treatment of diabetes

Independent studies done by universities and corporations have illustrated a remarkable increase in the yield of viable stem cells after cryopreservation using AAGP™ in the freeze-thaw process. One future approach to increasing diabetics’ insulin production is related to an ability to convert their stem cells into islet cells for transplantation. The feasibility of this procedure is dependent upon the amount of functioning islet cells that can be derived from the patient’s stem cells. This is where AAGP™ can make a very beneficial contribution.

13 Jan 2010

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

Spherix Inc., an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the completion of patient enrollment in its global Phase 3 clinical trial NEET (70971-004), which is evaluating the safety and efficacy of D-tagatose as an oral treatment for Type 2 diabetes mellitus.

12 Jan 2010

Insulin News and Research

Further Reading

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

ConjuChem Biotechnologies establishes special committee to explore strategic alternatives

Access Pharmaceuticals provides update on its Cobalamin insulin development program

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed

CBAI collaborates with Center for Stem Cell Awareness to re-sell its stem cell collection and storage services

Medpro Safety Products purchases product development rights from Visual Connections

Down syndrome and Alzheimer's disease are the same

MAGIC investigators identify new genetic variants that influence insulin and glucose regulation

Researchers identify new gene variants associated With glucose, insulin levels

Fourth edition of IDF Diabetes Atlas reports high incidence of diabetes in developing countries

Evidence suggests insulin pumps may help in maintaining blood glucose levels in type 1 diabetic patients

Researchers uncover novel genetic markers for diabetes-related traits

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Green tea could modulate smoke-induced lung cancer

ProtoKinetix’ AAGP raises hope for treatment of diabetes

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News